Back to news

Evotec Announces Chief Scientific Officer Transition

PR Newswire•29/09/2026•02:04 ET
0

Key Highlights

  • ➤Chief Scientific Officer Cord Dohrmann (EVO) steps down September 30, 2026
  • ➤Dohrmann and Evotec (EVO) reached a mutual-consent decision
  • ➤Successor search for Evotec’s (EVO) Chief Scientific Officer remains ongoing
  • ➤Dohrmann served as CSO and Management Board member since 2010

Expert Statements

Christian Wojczewski, Chief Executive Officer of Evotec

“I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years. Throughout his tenure, he has played a significant role in strengthening the scientific excellence and innovation culture that Evotec is known for. With his strategic vision for emerging technologies and future scientific trends, Cord has helped establish key capabilities across our platforms, including our iPSC-based technologies and omics capabilities, which have further reinforced Evotec's scientific leadership. Looking to the future, the robust science infrastructure that Cord has built will be an essential component of Evotec's future growth and profitability.”

Cord Dohrmann, Outgoing Chief Scientific Officer of Evotec

“The process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and I have been privileged to contribute to that progress during my time at Evotec. I am grateful for the support and collaboration of the many colleagues I have worked with in that time and look forward to seeing Evotec's scientific expertise continue to create value for customers, partners and patients.”

Evotec Announces Chief Scientific Officer Transition PR Newswire

* Dr. Cord Dohrmann to step down as of September 30, 2026 * Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in